{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+%28Human%29&page=2", "query": { "intervention": "Immune Globulin (Human)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 1654, "total_pages": 166, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+%28Human%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+%28Human%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T19:21:14.551Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03384745", "title": "A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "M1095 (Sonelokimab)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bond Avillion 2 Development LP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 313, "start_date": "2018-07-31", "completion_date": "2020-03-26", "has_results": true, "last_update_posted_date": "2021-08-03", "last_synced_at": "2026-10-08T19:21:14.551Z", "location_count": 11, "location_summary": "Birmingham, Alabama • San Diego, California • DeLand, Florida + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03384745" }, { "nct_id": "NCT00086671", "title": "Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "ABT-874/Human monoclonal antibody against IL-12", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 215, "start_date": "2004-04", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-01-04", "last_synced_at": "2026-10-08T19:21:14.551Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Laguna Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00086671" }, { "nct_id": "NCT04023019", "title": "Treatment of Hemophilia A Patients With FVIII Inhibitors", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "Nuwiq", "type": "BIOLOGICAL" }, { "name": "Octanate", "type": "BIOLOGICAL" }, { "name": "Wilate", "type": "BIOLOGICAL" }, { "name": "Emicizumab", "type": "BIOLOGICAL" }, { "name": "Recombinant factor VIIa (rFVIIa)", "type": "BIOLOGICAL" }, { "name": "Activated prothrombin complex concentrate (aPCC)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 120, "start_date": "2020-03-17", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-08T19:21:14.551Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04023019" }, { "nct_id": "NCT04028063", "title": "Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Soft Tissue Sarcoma", "Advanced Soft Tissue Sarcoma" ], "interventions": [ { "name": "Balstilimab", "type": "DRUG" }, { "name": "Zalifrelimab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Botensilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 65, "start_date": "2020-01-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-08T19:21:14.551Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04028063" }, { "nct_id": "NCT02452463", "title": "Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Squamous Non-Small Cell Carcinoma", "Radiation-Induced Pneumonitis", "Stage II Lung Non-Small Cell Cancer AJCC v7", "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIB Lung Non-Small Cell Carcinoma AJCC v7", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Nintedanib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-06-29", "completion_date": "2019-06-10", "has_results": true, "last_update_posted_date": "2020-04-06", "last_synced_at": "2026-10-08T19:21:14.551Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02452463" }, { "nct_id": "NCT05030831", "title": "Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ATP-Binding Cassette Subfamily C Member 6 Deficiency", "Pseudoxanthoma Elasticum", "Generalized Arterial Calcification of Infancy" ], "interventions": [ { "name": "INZ-701", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inozyme Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 10, "start_date": "2022-04-11", "completion_date": "2024-07-09", "has_results": false, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-10-08T19:21:14.551Z", "location_count": 1, "location_summary": "Eatontown, New Jersey", "locations": [ { "city": "Eatontown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05030831" }, { "nct_id": "NCT05377528", "title": "Study of AGEN1571 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "AGEN1571", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Botensilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-07-19", "completion_date": "2024-12-23", "has_results": false, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-10-08T19:21:14.551Z", "location_count": 6, "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05377528" }, { "nct_id": "NCT05684692", "title": "Screening Trial for Pain Relief in Schwannomatosis (STARFISH)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schwannomatosis", "Schwannomas", "Pain, Chronic" ], "interventions": [ { "name": "Siltuximab", "type": "DRUG" }, { "name": "Erenumab-Aooe", "type": "DRUG" }, { "name": "Siltuximab Matching Placebo", "type": "DRUG" }, { "name": "Erenumab-Aooe Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-08-31", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-08T19:21:14.551Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05684692" }, { "nct_id": "NCT01629511", "title": "Allogeneic Stem Cell Transplant for CLL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Allogeneic Hematopoietic Stem Cell Transplantation Recipient", "Chronic Lymphocytic Leukemia", "Prolymphocytic Leukemia", "Richter Syndrome" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2012-11-21", "completion_date": "2018-04-25", "has_results": true, "last_update_posted_date": "2020-02-24", "last_synced_at": "2026-10-08T19:21:14.551Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01629511" }, { "nct_id": "NCT00989651", "title": "Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Carcinoma", "Fallopian Tube Carcinosarcoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Neoplasm", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Brenner Tumor", "Ovarian Carcinoma", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Tumor", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 431, "start_date": "2009-10-28", "completion_date": "2020-04-10", "has_results": false, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-10-08T19:21:14.551Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Augusta, Georgia + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00989651" } ] }